A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1563-1570

  Heo, Jeong ^a,b   Park, Jun Yong ^b,c   Lee, Heon Ju ^b,d   Tak, Won Young ^b,e   Um, Soon Ho ^b,f   Kim, Do Young ^b,c   Yoon, Ki Tae ^a,b   Park, Soo Young ^b,e   Seo, Yeon Seok ^b,f   Han, Kwang Hyub ^b,c,g   Cho, Mong ^a,b   Ahn, Sang Hoon ^b,c,g  

^a Pusan National University School of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84871894884     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2277     Document Type: Article

References (38)

1. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15:1356-1361. (Pubitemid 32052906)
2. Mohamed R, Desmond P, Suh DJ, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19:958-969. (Pubitemid 39237427)
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
4. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002; 17:457-462.
5. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15:5761-5769.
6. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005; 48:133-137.
7. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-1143.
8. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53:1494-1498. (Pubitemid 39265273)
9. Park JY, Park YN, Kim DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat 2008; 15:615-621.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
11. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
12. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
13. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722. (Pubitemid 37500436)
14. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9:257-262.
15. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696. (Pubitemid 36337972)
16. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-1282.
17. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117. (Pubitemid 36055344)
18. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532. (Pubitemid 32496991)
19. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180. (Pubitemid 30452590)
20. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68. (Pubitemid 28304879)
21. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226. (Pubitemid 34700781)
22. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
23. Lee JM, Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010; 15:235-241.
24. EASL Clinical Practice Guidelines. management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
25. Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4:386-395.
26. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
27. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10:441-449. (Pubitemid 41151022)
28. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16:77-87.
29. Chon YE, Kim SU, Lee CK, et al. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther 2011; 16:469-477.
30. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53:1486-1493.
31. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53:885-894.
32. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108. (Pubitemid 351975535)
33. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: Influenece of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52:493-500.
34. Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 2010; 17:123-129.
35. Lee JM, Ahn SH, Chang HY, et al. [Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry]. Korean J Hepatol 2004; 10:260-270. Korean.
36. Kim JK, Chang HY, Lee JM, et al. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol 2009; 81:1002-1008.
37. Ahn SH, Yuen L, Han KH, et al. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol 2010; 82:1126-1134.
38. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23:1320-1326.